(NVO) Novo Nordisk - Ratings and Ratios
Diabetes, Obesity, Insulin, Hormone, RareDisease
NVO EPS (Earnings per Share)
NVO Revenue
Description: NVO Novo Nordisk
Novo Nordisk A/S is a leading pharmaceutical company with a strong presence in the global market, operating in two main segments: Diabetes and Obesity Care, and Rare Disease. The companys product portfolio includes a range of pharmaceuticals and medical devices, such as insulin pens, growth hormone pens, and injection needles, as well as smart solutions for diabetes treatment.
The companys Diabetes and Obesity Care segment is a key growth driver, with a strong pipeline of products and a significant presence in emerging therapy areas. Novo Nordisks commitment to innovation is evident in its collaboration with Valo Health, Inc. to develop novel drug programs for cardiometabolic diseases. Additionally, the companys partnership with UNICEF to tackle childhood obesity highlights its focus on addressing significant public health issues.
From a financial perspective, Novo Nordisks key performance indicators (KPIs) are impressive, with a high Return on Equity (RoE) of 81.24% indicating strong profitability. The companys dividend yield is also attractive, making it a compelling investment opportunity for income-seeking investors. Furthermore, Novo Nordisks revenue growth has been driven by the increasing demand for its diabetes and obesity care products, with a strong presence in key markets such as North America and Europe.
To further evaluate the companys prospects, its essential to analyze its revenue breakdown by segment and geography, as well as its research and development (R&D) pipeline. With a significant R&D investment, Novo Nordisk is well-positioned to drive future growth through innovation. Key metrics to monitor include the companys sales growth, gross margin, and operating expenses as a percentage of revenue.
NVO Stock Overview
| Market Cap in USD | 199,592m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1982-01-04 |
NVO Stock Ratings
| Growth Rating | 27.9 |
| Fundamental | 89.8% |
| Dividend Rating | 64.8 |
| Rel. Strength | -55.8 |
| Analysts | 3.50 of 5 |
| Fair Price Momentum | 44.29 USD |
| Fair Price DCF | 360.35 USD |
NVO Dividends
| Dividend Yield 12m | 2.43% |
| Yield on Cost 5y | 5.23% |
| Annual Growth 5y | 17.29% |
| Payout Consistency | 93.9% |
| Payout Ratio | 6.5% |
NVO Growth Ratios
| Growth Correlation 3m | -39.5% |
| Growth Correlation 12m | -92.3% |
| Growth Correlation 5y | 84% |
| CAGR 5y | 10.12% |
| CAGR/Max DD 5y | 0.15 |
| Sharpe Ratio 12m | -0.71 |
| Alpha | -81.01 |
| Beta | 0.899 |
| Volatility | 77.14% |
| Current Volume | 15467.9k |
| Average Volume 20d | 13724.2k |
| Stop Loss | 47 (-5.8%) |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (111.07b TTM) > 0 and > 6% of Revenue (6% = 18.72b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -5.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -14.37% (prev -4.03%; Δ -10.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 121.53b > Net Income 111.07b (YES >=105%, WARN >=100%) |
| Net Debt (80.83b) to EBITDA (118.34b) ratio: 0.68 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.44b) change vs 12m ago -0.54% (target <= -2.0% for YES) |
| Gross Margin 83.95% (prev 84.53%; Δ -0.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.26% (prev 69.85%; Δ 3.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.17 (EBITDA TTM 118.34b / Interest Expense TTM 11.57b) >= 6 (WARN >= 3) |
Altman Z'' 2.91
| (A) -0.09 = (Total Current Assets 162.71b - Total Current Liabilities 207.52b) / Total Assets 482.15b |
| (B) 0.34 = Retained Earnings (Balance) 164.45b / Total Assets 482.15b |
| (C) 0.28 = EBIT TTM 117.73b / Avg Total Assets 425.77b |
| (D) 0.52 = Book Value of Equity 164.45b / Total Liabilities 314.09b |
| Total Rating: 2.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.81
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 4.55% = 2.27 |
| 3. FCF Margin 19.87% = 4.97 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 0.84 = 1.98 |
| 6. ROIC - WACC 30.76% = 12.50 |
| 7. RoE 77.86% = 2.50 |
| 8. Rev. Trend 96.27% = 4.81 |
| 9. Rev. CAGR 19.04% = 2.38 |
| 10. EPS Trend 88.91% = 2.22 |
| 11. EPS CAGR 23.41% = 2.34 |
As of August 12, 2025, the stock is trading at USD 49.87 with a total of 15,467,914 shares traded.
Over the past week, the price has changed by +2.17%, over one month by -27.65%, over three months by -26.38% and over the past year by -60.84%.
Yes, based on ValueRay´s Fundamental Analyses, Novo Nordisk (NYSE:NVO) is currently (August 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 89.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVO is around 44.29 USD . This means that NVO is currently overvalued and has a potential downside of -11.19%.
Novo Nordisk has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold NVO.
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
According to our own proprietary Forecast Model, NVO Novo Nordisk will be worth about 49.5 in August 2026. The stock is currently trading at 49.87. This means that the stock has a potential downside of -0.66%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67.7 | 35.7% |
| Analysts Target Price | 92.5 | 85.4% |
| ValueRay Target Price | 49.5 | -0.7% |
NVO Fundamental Data Overview
CCE Cash And Equivalents = 18.43b DKK (Cash only, last quarter)
P/E Trailing = 12.5995
P/E Forward = 12.3609
P/S = 0.6398
P/B = 8.3086
P/EG = 1.3016
Beta = 0.274
Revenue TTM = 311.94b DKK
EBIT TTM = 117.73b DKK
EBITDA TTM = 118.34b DKK
Long Term Debt = 87.31b DKK (from longTermDebt, last quarter)
Short Term Debt = 11.96b DKK (from shortLongTermDebt, last quarter)
Debt = 99.27b DKK (Calculated: Short Term 11.96b + Long Term 87.31b)
Net Debt = 80.83b DKK (from netDebt column, last quarter)
Enterprise Value = 1363.11b DKK (1282.28b + Debt 99.27b - CCE 18.43b)
Interest Coverage Ratio = 10.17 (Ebit TTM 117.73b / Interest Expense TTM 11.57b)
FCF Yield = 4.55% (FCF TTM 61.99b / Enterprise Value 1363.11b)
FCF Margin = 19.87% (FCF TTM 61.99b / Revenue TTM 311.94b)
Net Margin = 35.61% (Net Income TTM 111.07b / Revenue TTM 311.94b)
Gross Margin = 83.95% ((Revenue TTM 311.94b - Cost of Revenue TTM 50.07b) / Revenue TTM)
Tobins Q-Ratio = 8.29 (Enterprise Value 1363.11b / Book Value Of Equity 164.45b)
Interest Expense / Debt = 4.99% (Interest Expense 4.96b / Debt 99.27b)
Taxrate = 20.60% (from yearly Income Tax Expense: 26.20b / 127.19b)
NOPAT = 93.48b (EBIT 117.73b * (1 - 20.60%))
Current Ratio = 0.78 (Total Current Assets 162.71b / Total Current Liabilities 207.52b)
Debt / Equity = 0.59 (Debt 99.27b / last Quarter total Stockholder Equity 168.07b)
Debt / EBITDA = 0.84 (Net Debt 80.83b / EBITDA 118.34b)
Debt / FCF = 1.60 (Debt 99.27b / FCF TTM 61.99b)
Total Stockholder Equity = 142.65b (last 4 quarters mean)
RoA = 23.04% (Net Income 111.07b, Total Assets 482.15b )
RoE = 77.86% (Net Income TTM 111.07b / Total Stockholder Equity 142.65b)
RoCE = 51.20% (Ebit 117.73b / (Equity 142.65b + L.T.Debt 87.31b))
RoIC = 39.71% (NOPAT 93.48b / Invested Capital 235.40b)
WACC = 8.94% (E(1282.28b)/V(1381.55b) * Re(9.33%)) + (D(99.27b)/V(1381.55b) * Rd(4.99%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -100.0 | Cagr: -0.62%
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.87% ; FCFE base≈63.60b ; Y1≈69.72b ; Y5≈88.71b
Fair Price DCF = 360.4 (DCF Value 1213.85b / Shares Outstanding 3.37b; 5y FCF grow 11.02% → 2.90% )
Revenue Correlation: 96.27 | Revenue CAGR: 19.04%
Revenue Growth Correlation: -71.38%
EPS Correlation: 88.91 | EPS CAGR: 23.41%
EPS Growth Correlation: -57.89%
Additional Sources for NVO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle